Last reviewed · How we verify

NCT04863144

Pharmacokinetics of Paclitaxel in Correlation With Adverse Events in Cancer Patients With and Without Liver Impairment

Status unknown Last updated 28 April 2021
What this trial tests

trial testing Blood samples in Liver Diseases in 40 participants. Status unknown.

Timeline
1 August 2020
Primary endpoint
1 December 2021
1 February 2022

Quick facts

Lead sponsorAin Shams University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment40
Start date1 August 2020
Primary completion1 December 2021
Estimated completion1 February 2022
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Adults 18 to 70, any sex, with Liver Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to assess the pharmacokinetics of paclitaxel and its two major metabolites in patients with normal and impaired liver functions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Blood samples

Trials testing the same drug.

Other recruiting trials for Liver Diseases

Currently open trials in the same condition.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04863144.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing